German industrial conglomerate Siemens AG took another major step toward restructuring when it unveiled a plan on Nov. 4 that includes the divestiture of businesses with annual sales of $10.2 billion. Unaffected by the restructuring is the company’s
German industrial conglomerate Siemens AG took another major step toward restructuring when it unveiled a plan on Nov. 4 that includes the divestiture of businesses with annual sales of $10.2 billion. Unaffected by the restructuring is the companys Medical Engineering Group, which continues to post an encouraging turnaround, according to the company.
Siemens AG president and CEO Heinrich von Pierer has been restructuring the company for the past year, shedding underperforming business units. This months news represents the most radical move yet in his campaign to reshape Siemens, however.
The bulk of Von Pierers plans involve the companys Components group, which consists of operations in semiconductors, passive components and electron tubes, and electromechanical components. The semiconductors business will be spun off as an independent company, while Siemens is still examining its options for the passive components and electron tubes business. Siemens is also seeking a partner for the electromechanical components business. The businesses to be divested have annual sales of about $10.2 billion.
Siemens reported that operations in its Medical Engineering Group have improved significantly since the unit reported an operating loss last year. Medical Engineering reported annual sales of $4.5 billion, up 11% compared with sales from continuing operations last year. The groups operating profit before taxes was $100.3 million, compared with a loss of $102.1 million the year before.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.